Roivant Sciences (NASDAQ:ROIV – Get Free Report) had its price objective hoisted by equities researchers at HC Wainwright from $41.00 to $47.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 10.64% from the stock’s current price.
Several other equities analysts also recently commented on the company. Sanford C. Bernstein upgraded Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Tuesday, August 25th. Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a research report on Friday, July 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Roivant Sciences in a report on Wednesday, August 19th. Finally, Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $37.68.
View Our Latest Report on ROIV
Roivant Sciences Price Performance
Roivant Sciences (NASDAQ:ROIV – Get Free Report) last posted its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The firm had revenue of $1.44 million for the quarter, compared to analysts’ expectations of $2.06 million. On average, analysts forecast that Roivant Sciences will post -2 EPS for the current year.
Insiders Place Their Bets
In other news, Director Daniel Gold sold 800,000 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $34.55, for a total value of $27,640,000.00. Following the sale, the director directly owned 13,701,546 shares of the company’s stock, valued at approximately $473,388,414.30. This represents a 5.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Mayukh Sukhatme sold 284,707 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $36.25, for a total transaction of $10,320,628.75. Following the sale, the insider owned 18,630,739 shares of the company’s stock, valued at approximately $675,364,288.75. This trade represents a 1.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 3,055,913 shares of company stock worth $107,261,258. 8.80% of the stock is currently owned by insiders.
Institutional Trading of Roivant Sciences
Large investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC acquired a new position in shares of Roivant Sciences during the 1st quarter valued at $3,957,000. Bank of America Corp DE grew its holdings in Roivant Sciences by 8.0% in the first quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock worth $87,638,000 after purchasing an additional 235,493 shares during the period. Baader Bank Aktiengesellschaft acquired a new stake in Roivant Sciences in the fourth quarter worth $1,029,000. Nicholas Investment Partners LP increased its stake in Roivant Sciences by 13.9% in the fourth quarter. Nicholas Investment Partners LP now owns 279,856 shares of the company’s stock valued at $6,073,000 after purchasing an additional 34,235 shares in the last quarter. Finally, Jefferies Financial Group Inc. bought a new stake in Roivant Sciences in the fourth quarter valued at $76,272,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.
Key Roivant Sciences News
Here are the key news stories impacting Roivant Sciences this week:
- Positive Sentiment: Roivant and its Pulmovant subsidiary reported positive Phase 2 PHocus results for mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD), a serious condition with substantial unmet medical needs. The company also disclosed that the Phase 3 PHrontier study is underway, providing a potential path toward a larger value-creating catalyst. Roivant Announces Positive Results from PHocus Study
- Positive Sentiment: Coverage highlighted that mosliciguat met the goals of its mid-stage study, helping drive investor enthusiasm and positioning the drug as a potentially important lung-disease asset. Roivant’s Experimental Lung Disease Drug Meets Goals
- Positive Sentiment: Jefferies raised its price target for ROIV to $52 from $42 and maintained a Buy rating, reflecting increased confidence following the clinical update. Unusually heavy call-option buying also indicates elevated near-term bullish speculation.
- Positive Sentiment: Roivant and Priovant reportedly received FDA approval for Lisraya, described as the first oral treatment for dermatomyositis. The approval gives the partners a differentiated commercial product in a rare disease with limited treatment options. Roivant Wins Approval for the First Oral Dermatomyositis Drug
- Neutral Sentiment: Lisraya launched with a reported list price of $35,000 per 30-day supply, underscoring substantial revenue potential but leaving reimbursement, patient access, and adoption as key commercial risks. What Lisraya’s $35,000 Monthly Price Could Mean for Roivant
Roivant Sciences Company Profile
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.
Read More
- Five stocks we like better than Roivant Sciences
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
- AI Is Making Cybersecurity Harder to Ignore—These 3 ETFs Offer a Broad Bet
- Campbell’s Dividend Cut May Reset the Stock, But the Turnaround Still Has to Deliver
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
